Abstract
In parallel with the expansion of PET imaging to pediatric patients has been the technological development of merging state-of-the-art cross-sectional anatomic information (CT) with functional imaging (PET) into a single modality: PET–CT. Attending to the clinical, scheduling, and medical needs that are unique to imaging children and adolescents can be a challenge, particularly when instituting a single new modality. When that modality bridges two unique, previously independent methods—often previously located in two separate departmental divisions—the details and logistics required to set up a smoothly functioning process can be particularly difficult. This paper focuses on our experience in implementing PET–CT in a tertiary pediatric referral center.
Similar content being viewed by others
References
Antoch G, Freudenberg LS, Strattus J, et al (2002) Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR 179:1555–1560
Dizendorf EV, Treyer V, von Schulthess GK, et al (2002) Application of oral contrast media in coregistered positron emission tomography-CT. AJR 179:477–481
Holbrook S (2002) 18-FDG PET whole-body imaging: developing an oncology protocol. Adv Imag Radiat Ther 15:9
Goerres GW, von Schulthess GK, Hany TF (2002) Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR 179:1337-1343
Kostakiglu L, Agress H, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23:315–340
Daldrup-Link HE, Franzius C, Link TM, et al (2001) Whole-body imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR 177:229–236
Hawkins DS, Rajendran JG, Conrad EU III, et al (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94:3277–3284
Brenner W, Bohuslavizki KH, Eary JF (2003) PET imaging of osteosarcoma. J Nucl Med 44:930–942
Bredella MA, Caputo GR, Steinback LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR 179:1145–1150
Franzius C, Sciuk J, Daldrup-Link HE, et al (2000) PDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311
Shulkin BL, Mitchell DSA, Ungar DR, et al (1995) Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-d-glucose PET studies. Radiology 194:495–500
Shulkin BL, Hutchinson RJ, Castle VP, et al (1996) Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-doexy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743–750
Kushner BH, Yeung HWD, Larson SM, et al (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up patients. J Clin Oncol 19:3397–3405
Scharko AM, Perlman SC, Pyzalski RW, et al (2003) Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 362:959–961
Iyengar S, Chin B, Margolick JB, et al (2003) Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 362:945–950
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by grants P30 CA-21765 and P01 CA-20180 from the National Cancer Institute, a Center of Excellence grant from the state of Tennessee from the National Institutes of Health, and by the American Lebanese Syrian Associated Charities (ALSAC)
CME activity Please find the CME information and questions at the end of this issue
The author(s) have no financial interest, arrangement, or affiliation to disclose in the context of this CME activity. There is nothing to disclose regarding investigational or “off-label” use of medical devices or other products, or any pharmaceutical agents
Rights and permissions
About this article
Cite this article
Kaste, S.C. Issues specific to implementing PET–CT for pediatric oncology: what we have learned along the way. Pediatr Radiol 34, 205–213 (2004). https://doi.org/10.1007/s00247-003-1111-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-003-1111-6